CD4+ T-cell reactivity to orexin/hypocretin in patients with narcolepsy type 1

Sleep

Volumn 40, Issue 3, 2017, Pages

  Ramberger, Melanie ^a   Högl, Birgit ^a   Stefani, Ambra ^a   Mitterling, Thomas ^a,b   Reindl, Markus ^a   Lutterotti, Andreas ^a,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Autoimmune disease; CD4+ T cell proliferation; HLA DQB1 06:02; Narcolepsy type 1; Orexin hypocretin

Indexed keywords

CARBOXYFLUORESCEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DQB1 ANTIGEN; OREXIN; SIGNAL PEPTIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DIVISION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE FREQUENCY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; NARCOLEPSY; NARCOLEPSY TYPE 1; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; BLOOD; CELL CULTURE; CHILD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NERVE CELL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHILD; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NARCOLEPSY; NEURONS; OREXINS; YOUNG ADULT;

EID: 85017184076     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/zsw070     Document Type: Article

References (53)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007; 369(9560): 499-511.
2. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed. (ICSD-3). Darien, IL; 2014.
3. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001; 57(11): 2029-2033.
4. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007; 30(1): 13-26.
5. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000; 27(3): 469-474.
6. Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009; 32(8): 993-998.
7. Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol. 2003; 13(3): 340-351.
8. Mignot E, Lin X, Arrigoni J, et al. DQB1∗0602 and DQA1∗0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994; 17(8): S60-S67.
9. Mignot E. Genetics of narcolepsy and other sleep disorders. Am J Hum Genet. 1997; 60(6): 1289-1302.
10. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens. 1984; 24(5): 316-319.
11. Langdon N, Welsh KI, van Dam M, Vaughan RW, Parkes D. Genetic markers in narcolepsy. Lancet. 1984; 2(8413): 1178-1180.
12. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001; 68(3): 686-699.
13. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998; 50(2): S16-S22.
14. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002; 59(10): 1553-1562.
15. Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E. HLA DR15 (DR2) and DQB1∗0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology. 1997; 48(6): 1550-1556.
16. Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2014; 37(1): 19-25.
17. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009; 41(6): 708-711.
18. Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013; 9(2): e1003270.
19. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet. 2011; 43(1): 66-71.
20. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011; 70(3): 410-417.
21. Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol. 2013; 73(4): 560.
22. Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014; 50: 1-11.
23. Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015; 7(294): 294ra105.
24. Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP. A functional autoantibody in narcolepsy. Lancet. 2004; 364(9451): 2122-2124.
25. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010; 120(3): 713-719.
26. Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokunaga K, Honda M. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep. 2010; 33(7): 875-878.
27. Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010; 33(7): 869-874.
28. Katzav A, Arango MT, Kivity S, et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun. 2013; 45: 24-30.
29. Tanaka S, Honda Y, Honda M, Yamada H, Honda K, Kodama T. Anti-tribbles pseudokinase 2 (TRIB2)-immunization modulates HYPOCRETIN/OREXIN neuronal functions. Sleep 2016Sep 9. pii: sp-00219-16 [Epub ahead of print]
30. Bergman P, Adori C, Vas S, et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc Natl Acad Sci USA. 2014; 111(35): E3735-E3744.
31. Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015; 14(3): 318-328.
32. De la Herran-Arita AK, Kornum BR, Mahlios J, et al. Retraction of the research article: "CD4(+) T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy". Sci Transl Med 2014; 6: 247rt1.
33. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Does autoreactivity have a role in narcolepsy? Lancet Neurol. 2014; 13(11): 1072-1073.
34. Dauvilliers Y, Bauer J, Rigau V, et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol. 2013; 70(10): 1305-1310.
35. Ollila HM, Ravel JM, Han F, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet. 2015; 96(1): 136-146.
36. Tafti M, Lammers GJ, Dauvilliers Y, et al. Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep. 2016; 39(3): 581-587.
37. Bernard-Valnet R, Yshii L, Quériault C, et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci USA. 2016; 113(39): 10956-10961.
38. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, 2nd ed. (ICSD-2). Westchester, IL; 2005.
39. Siebold C, Hansen BE, Wyer JR, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA. 2004; 101(7): 1999-2004.
40. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013; 5(188): 188ra75.
41. Ambati A, Poiret T, Svahn BM, et al. Increased beta-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. J Intern Med. 2015; 278(3): 264-276.
42. Sakurai T, Moriguchi T, Furuya K, et al. Structure and function of human prepro-orexin gene. J Biol Chem. 1999; 274(25): 17771-17776.
43. Lee JH, Bang E, Chae KJ, Kim JY, Lee DW, Lee W. Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B. Eur J Biochem. 1999; 266(3): 831-839.
44. Yucesoy B, Talzhanov Y, Johnson VJ, et al. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine. 2013; 31(46): 5381-5391.
45. Posteraro B, Pastorino R, Di Giannantonio P, et al. The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses. Vaccine. 2014; 32(15): 1661-1669.
46. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000; 6(10): 1167-1175.
47. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014; 15(5): 502-507.
48. Statistik Austria. Impfschutz 2014. http://www.statistik.at/web-de/statistiken/menschen-und-gesellschaft/gesundheit/gesundheitsversorgung/gesundheitsvorsorge/index.html. Accessed June 29, 2016.
49. Mereckiene J. Seasonal influenza vaccination in Europe - Overview of vaccination recommendations and coverage rates in the EU Member States for the 2012-13 influenza season. Stockholm: European Centre for Disease Prevention and Control. 2015, p. 11. doi:10.2900/693898.
50. Dauvilliers Y, Jaussent I, Lecendreux M, et al. Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study. Brain Behav Immun. 2014; 37: 260-266.
51. Lecendreux M, Libri V, Jaussent I, et al. Impact of cytokine in type 1 narcolepsy: role of pandemic H1N1 vaccination ? J Autoimmun. 2015; 60: 20-31.
52. Tanaka S, Honda M, Toyoda H, Kodama T. Increased plasma IL-6, IL-8, TNF-alpha, and G-CSF in Japanese narcolepsy. Hum Immunol. 2014; 75(8): 940-944.
53. Kornum BR, Pizza F, Knudsen S, Plazzi G, Jennum P, Mignot E. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav Immun. 2015; 49: 54-58.